

CONTENTS

1. INTRODUCTION AND REVIEW OF LITERATURE.....	13
1.1 BREAST CANCER: LEADING CAUSE OF DEATH WORLDWIDE	14
1.2 BREAST CANCER TYPES AND TREATMENT.....	14
1.3 TUMOR MICROENVIRONMENT AND MODULATION OF IMMUNE RESPONSE FOR ANTI-CANCER THERAPY	15
1.4 ACTIVATION OF cGAS-STING PATHWAY:.....	17
1.5 cGAS: EMERGING ASSOCIATION WITH CANCER	20
1.6 cGAS-STING; MASTER REGULATOR OF INNATE IMMUNE RESPONSE DURING CHROMOSOMAL INSTABILITY AND DNA DAMAGE CONDITIONS	21
1.7 FACTORS MODULATING cGAS ACTIVITY DURING TUMORIGENESIS:	23
1.7.1 <i>dsDNA; cGAS does not differentiate between self and non-self-DNA</i>	23
1.7.2 <i>Phosphorylation of cGAS</i> :.....	23
1.7.3 <i>Ubiquitination of cGAS</i> :.....	24
1.7.4 <i>Other post-translational modifications of cGAS</i> :	25
1.7.5 <i>Acetylation of cGAS</i> :	25
1.7.6 <i>Mn²⁺ as a cofactor of cGAS</i> :	26
1.8 2'3'cGAMP AND OTHER CYCLIC DINUCLEOTIDES: CRITICAL FACTOR REGULATING cGAS AND STING PATHWAY:	28
1.9 STING ACTIVATION AND REGULATION:.....	29
1.9.1 <i>Ubiquitin-mediated regulation of STING</i> :.....	29
1.9.2 <i>Autophagy-mediated regulation of STING-mediated inflammation</i> :.....	30
1.9.3 <i>Negative regulators of STING-mediated pathways</i> :.....	30
1.9.4 <i>Metabolic reprogramming and STING</i> :	31
1.9.5 <i>Phosphodiesterase regulates STING activation</i>	32
1.10 DIFFERENTIAL EXPRESSION OF STING IN TUMORS DETERMINES TYPE-1 INTERFERON RESPONSE IN TME:	33
1.11 MODULATION OF cGAS–STING PATHWAY FOR TUMOR CELL-SPECIFIC APOPTOSIS:	34
1.12 cGAS-STING: EXPLOITATION IN ONCO-IMMUNOTHERAPY	35
1.13 STING AGONIST: NATURAL CYCLIC DINUCLEOTIDE MODIFIED OR SYNTHETIC:	37
1.13.2 <i>Cyclic dinucleotide</i> :.....	37
1.13.3 <i>Non-dinucleotide</i> :.....	39
1.14 THE EXPLOITATION OF cGAS-STING PATHWAY WITH COMBINATION TREATMENT FOR ANTI-CANCER THERAPY	40
2. AIMS AND OBJECTIVES	46
2.1. RATIONALE OF HYPOTHESIS	47
2.2. <i>Objectives</i>	48
3. MATERIALS AND METHODS.....	49
3.1. CELLS AND CELL CULTURE	50
3.2. PLASMIDS AND REAGENTS	50
3.3. GENERATION OF cGAS -sgRNA AND p65-sgRNA CLONES.....	51
3.4 TRANSFECTION.....	51
3.5 COLLECTION OF TISSUES.....	51
3.6 QUANTITATIVE ANALYSIS OF GENE EXPRESSION	52
3.7 WESTERN BLOT	52
3.8 NF-KB, IFN- β LUCIFERASE ASSAY AND IL-6 ELISA	53
3.9 CELL GROWTH INHIBITION ASSAY AND CLONOGENIC ASSAY	53
3.10 MOLECULAR DOCKING AND CELLULAR THERMAL SHIFT ASSAY	54
3.12 CELL SURFACE EXPRESSION OF PD-L1	55

3.13 FLUORESCENCE MICROSCOPY	55
3.14 PARP CLEAVAGE	55
3.15 3D SPHEROID INHIBITION ASSAY	55
3.16 SUBCELLULAR FRACTIONATION	56
3.17 SURVIVAL ANALYSIS	56
3.18 TIMER DATABASE ANALYSIS	56
3.19 STATISTICAL ANALYSIS	56
4. RESULTS AND DISCUSSION.....	58
4.1 EXPRESSION ANALYSIS OF CGAS AND STING IN BREAST CANCER.....	58
4.1.1 Expression analysis of cGAS and STING in different breast cancer cell lines.....	59
4.1.2 Expression analysis of cGAS and STING in breast cancer patients.....	60
4.1.3 Discussion	61
4.2 TO STUDY THE CROSSTALK BETWEEN CGAS AND STING AND ITS EFFECT ON TUMORIGENESIS OF BREAST CANCER.....	62
4.2.1 DNA damage induces NF- κ B activation in STING positive triple-negative breast cancer cells ..	63
4.2.2 STING mediated NF- κ B activation induces IL-6 expression in triple-negative breast cancer cells in DNA damage conditions:	66
4.2.3 The knockdown of STING sensitizes breast cancer cells to genotoxic stress and inhibits clonogenicity:.....	69
4.2.4 STING-mediated IL-6 induction enhances PD-L1 expression during DNA damage in triple-negative breast cancer cells	71
4.2.5 STAT3 inhibitor, HJC0152 and doxorubicin act synergistically in breast cancer cells to inhibit cell death.....	74
4.2.6 STING expression positively correlates with IL6 and PD-L1 expression and high STING expression in chemotherapy shows poor survival	76
4.2.7 Discussion:	78
4.3 TO STUDY OF THE CGAS-STING PATHWAY IN ANTICANCER THERAPY	82
4.3.1 c-di AMP induces STING-mediated IFN pathway in breast cancer cell lines:	83
4.3.2 c-di-AMP binds to STING	85
4.3.3 c-di- AMP activates cell death in ER/PR negative breast cancer cell lines	87
4.3.4 STING is essential for c-di-AMP induced cell death.....	89
4.3.5 IRF-3 is indispensable for c-di-AMP-induced apoptosis in ER-negative breast cancer cells.	90
4.3.6 c-di-AMP induces IRF-3 translocation to mitochondria and induces the mitochondrial-mediated intrinsic pathway of apoptosis.....	92
4.3.7 Discussion:	94
4.4 ACTIVATION OF CGAS AND ANTI-CANCER THERAPY	97
4.4.1 MnCl ₂ activates STING-mediated IFN response.....	98
4.4.2 cGAS and STING are indispensable for MnCl ₂ -mediated IFN activation in breast cancer cells	100
4.4.3 MnCl ₂ sensitizes breast cancer cells to paclitaxel-induced cell death:	101
4.4.4 Combination of MnCl ₂ and Paclitaxel enhanced immunogenic cell death of breast cancer cells.	103
4.4.5 Discussion:	105
5. SUMMARY AND CONCLUSION	107
5.1. SUMMARY:	108
5.1.1. Expression of cGAS and STING in breast cancer cell lines and patient tissue	108
5.1.2. Role of cGAS and STING during DNA damage conditions.....	108
5.1.3 Role of cGAS STING pathway in anti-cancer therapy	110
5.1.4. Role of cGAS STING pathway in anti-cancer therapy	111

5.2. CONCLUSION:	112
5.3. LIMITATION OF THE STUDY	114
5.4. FUTURE PERSPECTIVE	115
6. BIBLIOGRAPHY	116
7. LIST OF PUBLICATION.....	146
<i>a. Research Articles:</i>	<i>147</i>
<i>b. Review Article:</i>	<i>147</i>
B. PUBLICATIONS FROM OTHER ASSOCIATED PROJECTS DURING PH.D. TENURE	147
<i>a. Research Articles:</i>	<i>147</i>
<i>b. Poster Presentation in National and International Conference:.....</i>	<i>148</i>
8. REPRINTS OF PUBLISHED ARTICLES.....	149

LIST OF TABLES

TABLE-1 DIFFERENT DINUCLEOTIDES THAT ACTIVATE THE STING PATHWAY IN DIFFERENT PATHOGENIC CONDITIONS.....	28
TABLE-2 COMBINATION THERAPY FOR cGAS-STING PATHWAY AS ANTI-CANCER THERAPY.....	43